This review discusses the potential of targeting the kynurenine pathway (KP) in the treatment of inflammatory diseases. The KP, responsible for the catabolism of the amino acid tryptophan (TRP), produces metabolites that regulate various physiological processes, including inflammation, cell cycle, and neurotransmission. These metabolites, although necessary to maintain immune balance, may accumulate excessively during inflammation, leading to systemic disorders. Key KP enzymes such as indoleamine 2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2 (IDO2), tryptophan 2,3-dioxygenase (TDO), and kynurenine 3-monooxygenase (KMO) have been considered promising therapeutic targets. It was highlighted that both inhibition and activation of these enzymes may be beneficial, depending on the specific inflammatory disorder. Several inflammatory conditions, including autoimmune diseases, for which modulation of KP activity holds therapeutic promise, have been described in detail. Preclinical studies suggest that this modulation may be an effective treatment strategy for diseases for which treatment options are currently limited. Taken together, this review highlights the importance of further research on the clinical application of KP enzyme modulation in the development of new therapeutic strategies for inflammatory diseases.
Background:Due to their connection to inflammation and oxidative stress, tryptophan metabolites via the kynurenine pathway (KP) relate to important aspects of the pathophysiology of heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D). The study aimed to examine the relationship between parameters of HFpEF, measured with transesophageal echocardiography (TTE), and metabolites of the KP. Methods: One hundred and twenty subjects, 60 withT2D and 60 without, and 55 healthy controls were prospectively included in the current study. Liquid chromatography was used to quantify metabolites of KP in plasma. TTE was performed to assess the systolic and diastolic function of the left ventricle (LV). Results: Patients with T2D and HFpEF showed an increase in TRP, KYN, and AA concentrations (p=0.001, p<0.0001, p<0.0001, respectively) with a concomitant decrease in 3-HKYN (p=0.0009), and QA (p=0.0029) compared with those with HFpEF without diabetes. There were no significant differences in the morphology of the LV or left atrium, and even the parameters of LV diastolic function were comparable in both subgroups (HFpEF with T2D and HFpEF without T2D). Left ventricular global longitudinal strain (LVGLS) was significantly lower in HFpEF with T2D than in the subgroup of HFpEF patients without T2D (p=0.0026). Conclusion: Plasma levels of the kynurenine pathway metabolites were elevated in patients with HFpEF, and especially in patients with HFpEF and T2D. An increase in KP plasma metabolite concentrations were associated with LV remodeling and diastolic dysfunction.